论文部分内容阅读
目的:观察依达拉奉与丹红注射液联合治疗急性脑梗死的临床效果,并探讨其安全性。方法:对134例急性脑梗死患者的临床资料进行回顾性分析,将其分为AB两组,A组74例予以依达拉奉与丹红注射液联合治疗,B组60例仅予丹红注射液治疗,两组疗程均为2周。对两组的临床疗效与神经功能缺损评分予以对比观察。结果:两组治疗2周后,A组的总有效率达91.89%,B组总有效率仅76.66%,差异显著(P<0.05);A组患者神经功能缺损评分同B组相较,差异显著(P<0.05);A组中有4例患者出现轻度皮肤瘙痒,将输药滴速减慢后,症状得到缓解,B组中有4例患者ALT(丙氨酸)的氨基转移酶0升高,不良反应发生率对比,不具显著差异(P<0.05)。结论:应用依达拉奉联合丹红注射液治疗急性脑梗死,不仅安全可靠,效果显著,且不良反应较少,应予推广。
Objective: To observe the clinical effect of Edaravone and Danhong injection in the treatment of acute cerebral infarction and explore its safety. Methods: The clinical data of 134 patients with acute cerebral infarction were retrospectively analyzed, which were divided into two groups AB, 74 patients in group A were treated with edaravone and Danhong injection, 60 patients in group B were given only Danhong Injection treatment, two groups of treatment are 2 weeks. The clinical efficacy and neurological deficit scores were compared between the two groups. Results: After two weeks of treatment, the total effective rate of group A was 91.89%, while the total effective rate of group B was only 76.66% (P <0.05). The score of neurological deficit in group A was significantly higher than that of group B (P <0.05) .Among 4 patients in group A, mild pruritus appeared, the symptoms were relieved after the infusion drip speed was slowed down. In group B, 4 patients had ALT (alanine) aminotransferase 0 increased, the incidence of adverse reactions, no significant difference (P <0.05). Conclusion: Edaravone combined with Danhong injection in the treatment of acute cerebral infarction is not only safe and reliable, the effect is significant, and the adverse reaction is less, should be promoted.